J Public Health (2010) 18:327–335	51.02374267578125	32.88922119140625	8.4737548828125	121.04190063476562	0
DOI 10.1007/s10389-010-0315-0	51.02373504638672	44.34075927734375	8.46820068359375	113.98026275634766	0
REVIEW ARTICLE	56.692901611328125	64.282958984375	10.460693359375	85.86875915527344	1
Economic analysis based on multinational studies: methods	51.02360153198242	106.78515625	17.36480712890625	443.4223213195801	2
for adapting findings to national contexts	51.02360153198242	126.74078369140625	17.36480712890625	309.4997749328613	2
Thomas Reinhold & Bernd Brüggenjürgen &	51.02360153198242	162.34686279296875	9.962646484375	182.99155044555664	3
Michael Schlander & Stephanie Rosenfeld &	51.02360153198242	174.76263427734375	9.962646484375	179.76005935668945	3
Franz Hessel & Stefan N. Willich	51.02360153198242	187.23504638671875	9.962646484375	136.64717483520508	3
Received: 17 September 2009 / Accepted: 5 January 2010 / Published online: 5 February 2010	51.02360153198242	242.764404296875	8.46820068359375	322.4005012512207	4
# Springer-Verlag 2010	51.02360153198242	252.74249267578125	8.69598388671875	84.34412002563477	4
Abstract	51.02360153198242	282.36578369140625	9.96258544921875	36.6932487487793	5
Background Health economic parameters are increasingly	51.02360153198242	294.3457336425781	9.96258544921875	238.04933547973633	5
considered as variables in health care decisions, but	51.02360153198242	306.8179016113281	9.96258544921875	238.07124710083008	5
decision makers are interested in country-specific evalua-	51.02360153198242	319.2900695800781	9.96258544921875	238.08522415161133	5
tions. However, a large number of studies are performed in	51.02360153198242	331.7054748535156	9.96258544921875	238.07124710083008	5
foreign countries or in a multinational setting, which limits	51.02360153198242	344.1776428222656	9.96258544921875	238.03642654418945	5
the transferability to a single nation’s context.	51.02360153198242	356.6498107910156	9.96917724609375	185.4627571105957	5
Objective The present analysis summarises several of the	51.02360534667969	368.55511474609375	9.96258544921875	238.0553741455078	5
most common international methods for generating health	51.02360153198242	381.02728271484375	9.96258544921875	238.07027053833008	5
economic analyses based on clinical studies from different	51.02360153198242	393.49945068359375	9.96258544921875	238.10414505004883	5
settings.	51.02360153198242	405.91485595703125	9.96258544921875	32.65042495727539	5
Methods A narrative literature review was performed to	51.02360153198242	417.876953125	9.96258544921875	238.06831741333008	5
identify potential reasons for limited transferability of	51.02360153198242	430.34912109375	9.96258544921875	238.10612869262695	5
health economic evaluation results from one country to	51.02360153198242	442.8212890625	9.96258544921875	238.06727981567383	5
another. Based on these results, we searched the method-	51.02360153198242	455.2366943359375	9.96258544921875	238.0353889465332	5
ological literature for analytic approaches to handle the	51.02360153198242	467.7088623046875	9.96258544921875	238.05537796020508	5
restrictions. Additionally we describe the possibility of	51.02360153198242	480.1810302734375	9.96258544921875	238.07722854614258	5
transferring foreign economic study results to the country	51.02360153198242	492.596435546875	9.96258544921875	238.09917068481445	5
T. Reinhold (*) : B. Brüggenjürgen : S. N. Willich	51.02360153198242	523.2235717773438	13.004196166992188	176.4440803527832	6
Institute for Social Medicine, Epidemiology,	51.024261474609375	537.7376098632812	8.46820068359375	152.1837158203125	6
and Health Economics, Charité—University Medical Center,	51.024261474609375	547.6589965820312	8.4737548828125	207.96884155273438	6
Luisenstrasse 57,	51.024269104003906	557.6370239257812	8.46820068359375	58.490699768066406	6
10117 Berlin, Germany	51.024269104003906	567.6151123046875	8.46820068359375	80.74681854248047	6
e-mail: thomas.reinhold@charite.de	51.024269104003906	577.5932006835938	8.46820068359375	121.09610748291016	6
M. Schlander	51.024269104003906	597.4926147460938	8.46820068359375	45.907798767089844	7
Fachbereich Betriebswirtschaftlehre,	51.024269104003906	607.470703125	8.46820068359375	123.59929656982422	7
Hochschule Ludwigshafen am Rhein,	51.024269104003906	617.4487915039062	8.46820068359375	128.62519073486328	7
Ludwigshafen, Germany	51.024269104003906	627.3701171875	8.46820068359375	84.20523834228516	7
S. Rosenfeld : F. Hessel	51.024269104003906	642.7888793945312	13.005615234375	81.36107635498047	8
Sanofi-Aventis Deutschland GmbH,	51.02374267578125	657.2462158203125	8.46820068359375	122.71351623535156	8
Frankfurt, Germany	51.02374267578125	667.2243041992188	8.46820068359375	67.70748901367188	8
F. Hessel	51.02374267578125	687.180419921875	8.46820068359375	31.24596405029297	9
Institute for Medical Management, University of Duisburg-Essen,	51.02374267578125	697.101806640625	8.46820068359375	223.969482421875	9
Essen, Germany	51.02374267578125	707.0798950195312	8.46820068359375	55.688568115234375	9
of interest by matching trial data with routine data of	306.140869140625	282.3796081542969	9.96258544921875	238.07733154296875	10
national databases.	306.140869140625	294.8517761230469	9.96258544921875	75.40298461914062	10
Results The main factors for limited transferability of	306.140869140625	306.8138732910156	9.96258544921875	238.07757568359375	10
health economic findings were found in country-specific	306.140869140625	319.2860412597656	9.96258544921875	238.0662841796875	10
differences in resource consumption and the resulting costs.	306.140869140625	331.7014465332031	9.96258544921875	238.07037353515625	10
These differences are affected by a number of influencing	306.140869140625	344.1736145019531	9.96258544921875	238.09027099609375	10
cofactors (demography, epidemiology and individual	306.140869140625	356.6457824707031	9.96258544921875	238.1241455078125	10
patient’s factors) and the overall health care system	306.140869140625	369.0611877441406	9.96917724609375	238.072265625	10
structures (e.g. payment systems, health provider incentives).	306.140869140625	381.5333557128906	9.96258544921875	238.19384765625	10
However, despite the limitations country-specific health	306.140869140625	394.0055236816406	9.96258544921875	238.1510009765625	10
economic assessments could be realised using the pooled/	306.140869140625	406.4209289550781	9.96258544921875	238.07330322265625	10
split analyses approach, some statistical approaches and	306.140869140625	418.8930969238281	9.96258544921875	238.10125732421875	10
modelling approaches.	306.140869140625	431.3085021972656	9.96258544921875	88.55062866210938	10
Conclusion A variety of methods for identifying and	306.140869140625	443.2705993652344	9.96258544921875	238.11614990234375	10
adjusting country-specific differences in costs, effects and	306.140869140625	455.7427673339844	9.96258544921875	238.081298828125	10
cost-effectiveness was established during the past decades.	306.140869140625	468.2149353027344	9.96258544921875	238.10418701171875	10
Multinational studies will continue to play a crucial role in	306.140869140625	480.6303405761719	9.96258544921875	238.06817626953125	10
the evaluation of cost-effectiveness at national levels. It	306.140869140625	493.1025085449219	9.96258544921875	238.05126953125	10
seems likely that the growing interest in multinational	306.140869140625	505.57464599609375	9.96258544921875	238.03240966796875	10
studies will lead to continued developments in adaptation	306.140869140625	517.9900512695312	9.96258544921875	238.085205078125	10
methods.	306.140869140625	530.4622802734375	9.962615966796875	36.081573486328125	10
Keywords International adaption . Cost-effectiveness .	306.140869140625	553.3662719726562	11.947158813476562	216.61883544921875	11
Economic evaluation . Transferability	306.140869140625	565.8385009765625	11.947158813476562	147.41159057617188	11
Background	306.140869140625	605.1658935546875	9.962600708007812	52.357452392578125	12
The results of health economic evaluations are of growing	306.140869140625	630.0713500976562	9.962600708007812	238.03253173828125	13
interest to political decision makers and insurance pro-	306.140869140625	642.5435180664062	9.962600708007812	238.0452880859375	13
viders, not least because of increasingly tight budgets in the	306.140869140625	655.0156860351562	9.962608337402344	238.0562744140625	13
health care sector. To meet this new interest, clinical trials	306.140869140625	667.4310913085938	9.962600708007812	238.01654052734375	13
are increasingly taking into account resource and cost	306.140869140625	679.9032592773438	9.962600708007812	238.03839111328125	13
parameters (Drummond et al. 1997). In Germany economic	306.140869140625	692.3754272460938	9.962600708007812	238.06829833984375	13
aspects are becoming more important in the assessment of	306.140869140625	704.7908325195312	9.962600708007812	238.0771484375	13
328	51.02360153198242	33.0572509765625	8.46820068359375	12.702301025390625	14
new therapies. Moreover, numerous methodological stand-	51.02360153198242	58.333251953125	9.96258544921875	238.08317947387695	15
ards have been developed in recent years, which aim to	51.02360153198242	70.7486572265625	9.96258544921875	238.06926345825195	15
ensure that the results of clinical studies are less open to	51.02360153198242	83.2208251953125	9.96258544921875	238.06825637817383	15
bias. In addition, regulatory authorities tend to favour	51.02360153198242	95.6929931640625	9.96258544921875	238.0274543762207	15
designs in which at least a minority of subjects in trials	51.02360153198242	108.1083984375	9.96258544921875	238.0164680480957	15
have been recruited in the host country, although they	51.02360153198242	120.58056640625	9.96258544921875	238.04936599731445	15
remain generally content with the fact that only a minority	51.02360153198242	133.052734375	9.96258544921875	238.06328201293945	15
of subjects may actually be drawn from their country. Thus,	51.02360153198242	145.4681396484375	9.96258544921875	238.07527542114258	15
international multicentre study designs have become a key	51.02360153198242	157.9403076171875	9.96258544921875	238.08122634887695	15
component of clinical trial programmes (Demol and	51.02360153198242	170.4124755859375	9.96258544921875	238.13005447387695	15
Weihrauch 1997).	51.023597717285156	182.827880859375	9.96258544921875	71.57530212402344	15
Multinational studies have numerous advantages over	62.36204147338867	195.300048828125	9.96258544921875	226.84639358520508	15
single-nation studies. In particular, the large geographical	51.02360534667969	207.772216796875	9.96258544921875	238.18077087402344	15
areas involved allow investigators to recruit sizable numbers	51.02360534667969	220.1876220703125	9.96258544921875	238.0891571044922	15
of patients in a relatively short period of time, and the quality	51.02360534667969	232.6597900390625	9.96258544921875	238.1021270751953	15
of evidence may be improved by virtue of regional variations	51.02360534667969	245.1319580078125	9.96258544921875	238.1916961669922	15
in the patient mix (Manca and Willan 2006; Sculpher et al.	51.02360534667969	257.54736328125	9.96258544921875	238.10716247558594	15
2004; Drummond and Pang 2001). Multinational studies also	51.02360534667969	270.01953125	9.96258544921875	238.1938018798828	15
have important caveats. Chief among these is the difficulty	51.02259826660156	282.49169921875	9.96258544921875	238.1020965576172	15
of transferring study findings to the level of individual	51.02259826660156	294.9071044921875	9.96258544921875	238.18080139160156	15
national health care systems. After all, national decision	51.02259826660156	307.3792724609375	9.96258544921875	238.20567321777344	15
makers are primarily interested in the results a study would	51.02259826660156	319.8514404296875	9.96258544921875	238.1827850341797	15
have yielded if it had been conducted in their own	51.02259826660156	332.266845703125	9.96258544921875	238.1260528564453	15
jurisdiction.	51.02259826660156	344.739013671875	9.96258544921875	46.199562072753906	15
Clinical trials are normally designed on the assumption	62.36103439331055	357.1544189453125	9.96258544921875	226.7408332824707	15
of a common treatment effect across different strata, for	51.02259826660156	369.6265869140625	9.96258544921875	238.05235290527344	15
example by centre or by country. It is well understood that	51.02259826660156	382.0987548828125	9.96258544921875	238.0822296142578	15
patient characteristics and thus the absolute effects of	51.02259826660156	394.51416015625	9.96258544921875	238.0781707763672	15
treatment may vary between centres, and it is common to	51.02259826660156	406.986328125	9.96258544921875	238.0692596435547	15
use some form of stratified randomisation to ensure an	51.02259826660156	419.45849609375	9.96258544921875	238.0872039794922	15
approximate balance of treatment and control subjects	51.02259826660156	431.8739013671875	9.96258544921875	238.05726623535156	15
within centres or regions. The analysis of clinical trials	51.02259826660156	444.3460693359375	9.96258544921875	238.01649475097656	15
usually involves some degree of examination of subgroups,	51.02259826660156	456.8182373046875	9.96258544921875	238.0692596435547	15
although the aim is normally to support the assumption that	51.02259826660156	469.233642578125	9.96258544921875	238.08226013183594	15
there is a single treatment effect, and there is considerable	51.02259826660156	481.705810546875	9.96258544921875	238.0961456298828	15
controversy when it becomes apparent that this assumption	51.02259826660156	494.177978515625	9.96258544921875	238.07923889160156	15
may not be supported (Reed et al. 2005). The question of	51.02259826660156	506.5933837890625	9.96258544921875	238.0772247314453	15
transferability becomes very apparent, however, when we	51.023590087890625	519.0655517578125	9.96258544921875	238.04937744140625	15
consider economic parameters, for these—in contrast to	51.023590087890625	531.5377197265625	9.96917724609375	238.06924438476562	15
clinical outcomes—are subject to considerable country-	51.0225830078125	543.953125	9.969192504882812	238.07125854492188	15
specific variability (Asplund et al. 2003; Jönsson and	51.021583557128906	556.4253540039062	9.962600708007812	238.10216522216797	15
Weinstein 1997; Drummond and Pang 2001). Despite	51.02259826660156	568.8975219726562	9.962600708007812	238.09523010253906	15
recent efforts to develop methodological standards for	51.02162170410156	581.3129272460938	9.962600708007812	238.0852508544922	15
dealing with the resulting uncertainties, it is surprising to	51.02162170410156	593.7850952148438	9.962600708007812	238.0682830810547	15
see that economic analyses are still being conducted	51.02162170410156	606.2572631835938	9.962600708007812	238.12107849121094	15
without paying consideration to the issues raised when	51.02162170410156	618.6726684570312	9.962600708007812	238.0333709716797	15
transferring the findings of multinational studies to national	51.02162170410156	631.1448364257812	9.962600708007812	238.02345275878906	15
settings (Halliday and Darba 2003).	51.02162170410156	643.6170043945312	9.962600708007812	144.65296936035156	15
According to the most recent German health care reform	62.361061096191406	656.0324096679688	9.962600708007812	226.69698333740234	15
act from April 2007, the Institute for Quality and Efficiency	51.02262496948242	668.5045776367188	9.962600708007812	238.06828689575195	15
in Health Care (IQWiG) can be assigned to evaluate not	51.02262496948242	680.9767456054688	9.962600708007812	238.06233596801758	15
only the effects of a medical intervention according to	51.02262496948242	693.3921508789062	9.962600708007812	238.06926345825195	15
international standards of evidence-based medicine, but	51.02262496948242	705.8643188476562	9.962600708007812	238.0602912902832	15
J Public Health (2010) 18:327–335	423.21197509765625	33.0572509765625	8.4737548828125	121.0418701171875	16
also the balance between benefits in the national health care	306.139892578125	58.32025146484375	9.96258544921875	238.0494384765625	17
setting according to international standards of health	306.139892578125	70.73565673828125	9.96258544921875	238.14501953125	17
economics. In this context the question of transferring or	306.139892578125	83.20782470703125	9.96258544921875	238.07635498046875	17
adopting the findings of multinational trials to an actual	306.139892578125	95.67999267578125	9.96258544921875	238.07025146484375	17
national context will be a question of the methodological	306.139892578125	108.09539794921875	9.96258544921875	238.07025146484375	17
framework the IQWiG is currently about to implement.	306.139892578125	120.56756591796875	9.96258544921875	224.13861083984375	17
Objectives	306.139892578125	157.910400390625	9.962646484375	44.23992919921875	18
The present analysis summarises several of the most	306.139892578125	182.81585693359375	9.96258544921875	238.0810546875	19
common international methods for generating health eco-	306.139892578125	195.28802490234375	9.96258544921875	238.05126953125	19
nomic assessments based on clinical studies from different	306.139892578125	207.76019287109375	9.96258544921875	238.1051025390625	19
settings; it also provides an overview of potential new	306.139892578125	220.17559814453125	9.96258544921875	238.04144287109375	19
approaches to this subject from the perspective of Germany.	306.139892578125	232.64776611328125	9.96258544921875	238.10418701171875	19
In recent years, the problem of transferability has become	306.139892578125	245.11993408203125	9.96258544921875	238.09619140625	19
increasingly important in this country. These developments	306.139892578125	257.53533935546875	9.96258544921875	238.04833984375	19
raise the question of the extent to which the advantages of	306.139892578125	270.00750732421875	9.96258544921875	238.07525634765625	19
multinational studies can be reconciled with the need for	306.139892578125	282.47967529296875	9.96258544921875	238.0533447265625	19
unlimited transferability when adapting the findings of	306.139892578125	294.89508056640625	9.96258544921875	238.0772705078125	19
these studies to a specific national context.	306.139892578125	307.36724853515625	9.96258544921875	173.49868774414062	19
Methods	306.139892578125	344.71014404296875	9.96258544921875	36.712188720703125	20
A narrative literature review was performed to identify	306.139892578125	369.6165771484375	9.96258544921875	238.01348876953125	21
potential reasons for limited transferability of results of	306.139892578125	382.0887451171875	9.96258544921875	238.07635498046875	21
health economic evaluation from one country to another.	306.139892578125	394.504150390625	9.96258544921875	238.1041259765625	21
Although we used some relevant single search terms (e.g.	306.139892578125	406.976318359375	9.96258544921875	238.055419921875	21
“transferability”) and search term combinations [e.g. “trans-	306.139892578125	419.448486328125	9.96917724609375	238.04931640625	21
ferability” AND “cost-benefit analysis (MeSH term)”], the	306.140869140625	431.8638916015625	9.96917724609375	238.05926513671875	21
search procedure was not based on a systematic approach.	306.14080810546875	444.3360595703125	9.96258544921875	238.09521484375	21
Based on these results, we further searched the methodo-	306.14080810546875	456.8082275390625	9.96258544921875	238.0294189453125	21
logical literature for analytic approaches to handle the	306.14080810546875	469.2236328125	9.96258544921875	238.05731201171875	21
restrictions. Additionally we described the possibility of	306.14080810546875	481.69580078125	9.96258544921875	238.07427978515625	21
transferring foreign economic study results to the country	306.14080810546875	494.16796875	9.96258544921875	238.0992431640625	21
of interest by matching trial data with routine data from	306.14080810546875	506.5833740234375	9.96258544921875	238.072265625	21
national databases.	306.14080810546875	519.0555419921875	9.96258544921875	75.40298461914062	21
Results	306.14080810546875	556.3984375	9.962600708007812	30.652923583984375	22
Reasons for limited transferability	306.14080810546875	581.3038940429688	9.962600708007812	137.32546997070312	23
The transferability of cost and effectiveness results obtained	306.14080810546875	606.2482299804688	9.962600708007812	238.0633544921875	24
in multinational studies to national contexts can be limited	306.1416931152344	618.6859741210938	9.962600708007812	238.08230590820312	24
by a large number of factors (Bryan and Brown 1998;	306.1416931152344	631.1581420898438	9.962600708007812	238.07821655273438	24
Koopmanschap et al. 2001; Manca and Willan 2006). Here,	306.1416931152344	643.6303100585938	9.962600708007812	238.06930541992188	24
it is important to keep in mind that problems related to	306.1427001953125	656.0457153320312	9.962600708007812	238.0682373046875	24
transferability affect primarily economic findings (e.g.	306.1427001953125	668.5178833007812	9.962600708007812	238.09027099609375	24
resources or costs). A number of authors have described	306.1427001953125	680.9900512695312	9.962600708007812	238.08221435546875	24
the sources of limited transferability (Drummond and Pang	306.1427001953125	693.4054565429688	9.962600708007812	238.08123779296875	24
2001; Koopmanschap et al. 2001; O’Brien 1997; Pang	306.1427001953125	705.8776245117188	9.969131469726562	238.08319091796875	24
J Public Health (2010) 18:327–335	51.02360153198242	33.0572509765625	8.4737548828125	121.04190444946289	25
2002); some of these are briefly presented in the following	51.02360153198242	58.333251953125	9.96258544921875	238.06523513793945	26
section:	51.023597717285156	70.7486572265625	9.96258544921875	30.575218200683594	26
Differences in demography, epidemiology and individual	51.023597717285156	95.6929931640625	9.96258544921875	229.33507537841797	27
patient characteristics	51.023597717285156	108.1083984375	9.96258544921875	89.28380584716797	27
It is well known that individual patient characteristics have	51.023597717285156	133.052734375	9.96258544921875	238.0672836303711	28
at least an indirect influence on the effectiveness and cost-	51.023597717285156	145.4681396484375	9.96258544921875	238.07027435302734	28
effectiveness of any given intervention (Kaplan and Keil	51.023597717285156	157.9403076171875	9.96258544921875	238.0423812866211	28
1993). Examples include socioeconomic or demographic	51.023597717285156	170.4124755859375	9.96258544921875	238.0165023803711	28
factors, both of which may exhibit systematic country-	51.023597717285156	182.827880859375	9.96258544921875	238.07024383544922	28
specific differences in terms of their extent or degree. For	51.023597717285156	195.300048828125	9.96258544921875	238.0752182006836	28
instance, it is conceivable that patients in one country may	51.023597717285156	207.772216796875	9.96258544921875	238.05132293701172	28
show significant differences in educational attainment or	51.023597717285156	220.1876220703125	9.96258544921875	238.07622528076172	28
wealth compared to patients in the other countries taking	51.023597717285156	232.6597900390625	9.96258544921875	238.0921859741211	28
part in the same multinational study. This problem can be	51.023597717285156	245.1319580078125	9.96258544921875	238.09020233154297	28
addressed, where applicable, by defining strict inclusion	51.023597717285156	257.54736328125	9.96258544921875	238.1001205444336	28
criteria (Koopmanschap et al. 2001). Patient-reported out-	51.023597717285156	270.01953125	9.96258544921875	238.03838348388672	28
comes are also subject to regional variations and thus may	51.02360534667969	282.49169921875	9.96258544921875	238.04933166503906	28
also influence the evaluation of a treatment’s cost-	51.02360534667969	294.9071044921875	9.96917724609375	238.0841827392578	28
effectiveness (O’Brien 1997). The same can be said for	51.02360534667969	307.3792724609375	9.96917724609375	238.05433654785156	28
regional differences in the incidence and prevalence of a	51.02360534667969	319.8514404296875	9.96258544921875	238.09718322753906	28
particular disease. For instance, high prevalence of a	51.02360534667969	332.266845703125	9.96258544921875	238.0872039794922	28
disease in a certain country or region may lead to	51.02360534667969	344.739013671875	9.96258544921875	238.10411071777344	28
downstream experience curve effects on the part of local	51.02360534667969	357.1544189453125	9.96258544921875	238.07029724121094	28
health care providers. In turn, high incidence of a disease	51.02360534667969	369.6265869140625	9.96258544921875	238.0762481689453	28
can increase the cost-effectiveness of a given population-	51.02360534667969	382.0987548828125	9.96258544921875	238.0632781982422	28
wide preventive measure (Koopmanschap et al. 2001). The	51.02360534667969	394.51416015625	9.96258544921875	238.0981903076172	28
disease incidence and the level of patients’ comorbidities	51.02459716796875	406.986328125	9.96917724609375	238.072265625	28
will also be influenced by the age structure of a specific	51.02459716796875	419.45849609375	9.96258544921875	238.0155029296875	28
country’s population (Drummond and Pang 2001).	51.02459716796875	431.8739013671875	9.96917724609375	204.52120971679688	28
Differences in country-specific health care and analysis	51.02558898925781	456.8182678222656	9.96258544921875	225.47059631347656	29
structures	51.02558898925781	469.2336730957031	9.96258544921875	39.19984436035156	29
Additional factors that can limit the transferability of study	51.02558898925781	494.17803955078125	9.96258544921875	238.1270294189453	30
results from one country to another can be traced to differences	51.02558898925781	506.59344482421875	9.96258544921875	238.1150665283203	30
in the design and organisation of health care systems. Examples	51.02558898925781	519.0656127929688	9.96258544921875	238.0752716064453	30
include differing systems of physician reimbursement and	51.02558898925781	531.5377197265625	9.962615966796875	238.1250457763672	30
related incentive schemes (Koopmanschap et al. 2001;	51.02558898925781	543.9531860351562	9.962600708007812	238.07725524902344	30
Drummond and Pang 2001) as well as differences in pricing	51.02459716796875	556.4253540039062	9.962600708007812	238.084228515625	30
(Drummond and Pang 2001). In Germany, the method and	51.02459716796875	568.8975830078125	9.962600708007812	238.12109375	30
amount of physician reimbursement are based on consensus	51.02460479736328	581.3129272460938	9.962600708007812	238.13903045654297	30
agreements reached by the National Associations of Health	51.02460479736328	593.78515625	9.962600708007812	238.14400482177734	30
Insurance Funds and the National Associations of Social	51.02460479736328	606.25732421875	9.962600708007812	238.01644134521484	30
Health Insurance-accredited Physicians. In contrast, the remu-	51.02460479736328	618.6727294921875	9.962600708007812	238.07128143310547	30
neration of medical services in the USA is based on negotiated	51.02460479736328	631.1448974609375	9.962600708007812	238.10018157958984	30
contracts with health maintenance organisations (HMOs) or	51.02460479736328	643.6170654296875	9.962600708007812	238.00447845458984	30
other payers. For example, due to these differences, the US	51.02460479736328	656.032470703125	9.962600708007812	238.16790008544922	30
hospital care section is associated with comparably higher	51.02460479736328	668.504638671875	9.962600708007812	238.1130599975586	30
costs, which may lead to a higher utilisation in other health care	51.02460479736328	680.976806640625	9.962600708007812	237.97661590576172	30
areas (e.g. community services) in order to avoid the high	51.02460479736328	693.3922119140625	9.962600708007812	238.11214447021484	30
hospitalisation expenditures (Pang 2002).	51.02460479736328	705.8643798828125	9.962600708007812	158.3386001586914	30
329	531.5515747070312	33.0572509765625	8.46820068359375	12.7022705078125	31
A striking example of the relevance of varying unit costs	317.4793395996094	58.3203125	9.96258544921875	226.73678588867188	32
may be the choice of a cost-effective clinical pathway for	306.1408996582031	70.7357177734375	9.96258544921875	238.05142211914062	32
patients with peptic ulcer disease and dyspepsia. These	306.1408996582031	83.2078857421875	9.96258544921875	238.06423950195312	32
conditions are known to be associated with Helicobacter	306.1408996582031	95.6800537109375	9.96258544921875	238.02542114257812	32
pylori infection, and eradication of this bacterium has been	306.1408996582031	108.095458984375	9.96258544921875	238.06930541992188	32
shown to be an effective treatment strategy. H. pylori	306.1408996582031	120.567626953125	9.96258544921875	238.05728149414062	32
infection can be diagnosed by means of endoscopy or, less	306.14093017578125	133.039794921875	9.96258544921875	238.08319091796875	32
reliably, by non-invasive laboratory tests. The cost-	306.14093017578125	145.4552001953125	9.96258544921875	238.0213623046875	32
effectiveness of initial diagnosis of H. pylori infection by	306.14093017578125	157.9273681640625	9.96258544921875	238.09417724609375	32
means of gastroscopy appears to be highly sensitive to the	306.14093017578125	170.3995361328125	9.96258544921875	238.05926513671875	32
unit cost of the endoscopic procedure, which is much	306.14093017578125	182.81494140625	9.96258544921875	238.03948974609375	32
higher in the USA compared to European conventions	306.14093017578125	195.287109375	9.96258544921875	238.0244140625	32
(Bytzer 1999; Moayyedi 2007). As a consequence of this	306.14093017578125	207.75927734375	9.96258544921875	238.07525634765625	32
difference in cost, a clinical management strategy starting	306.14093017578125	220.1746826171875	9.96258544921875	238.08526611328125	32
with initial endoscopy has been described as a cost-	306.14093017578125	232.6468505859375	9.96258544921875	238.07122802734375	32
effective option in Europe, whereas in the USA empirical	306.14093017578125	245.1190185546875	9.96258544921875	238.05328369140625	32
antisecretory treatment or non-invasive H. pylori testing	306.14093017578125	257.534423828125	9.96258544921875	238.02545166015625	32
were identified as preferable options based on their cost-	306.1409606933594	270.006591796875	9.96258544921875	238.07125854492188	32
effectiveness (Bytzer 1999).	306.1409606933594	282.478759765625	9.96258544921875	113.01773071289062	32
Apart from unit costs, differences in country-specific	317.4794006347656	294.8941650390625	9.96258544921875	226.72775268554688	32
methods (upon which the economic evaluation is based)	306.1409606933594	307.3663330078125	9.96258544921875	238.02340698242188	32
could potentially influence the results of an economic	306.1409606933594	319.8385009765625	9.96258544921875	238.07431030273438	32
assessment. For example the cost-effectiveness perspective	306.1409606933594	332.25390625	9.96258544921875	238.06930541992188	32
could lead to different findings regarding the cost-	306.1409606933594	344.72607421875	9.96258544921875	238.07119750976562	32
effectiveness of a treatment. Was an analysis performed	306.1409606933594	357.1414794921875	9.96258544921875	238.00857543945312	32
out of a societal perspective including all indirect costs or	306.1416931152344	369.634033203125	9.96258544921875	238.07626342773438	32
from the point of view of a single health care participant	306.1416931152344	382.106201171875	9.96258544921875	238.06930541992188	32
(e.g. health insurance company)? Even if an analysis was	306.1416931152344	394.5216064453125	9.96258544921875	238.08718872070312	32
performed from the well-chosen perspective of interest, the	306.1416931152344	406.9937744140625	9.96258544921875	238.05624389648438	32
possibility for a single-country adaptation could be limited.	306.1416931152344	419.4659423828125	9.96258544921875	238.07827758789062	32
For example the economic evaluation results of a therapy	306.1416931152344	431.88134765625	9.96258544921875	238.09329223632812	32
from the perspective of a social insurance system will be	306.1416931152344	444.353515625	9.96258544921875	238.08816528320312	32
deeply influenced by the structure of this system. Such a	306.1416931152344	456.82568359375	9.96258544921875	238.09426879882812	32
social insurance system could include a health care	306.1416931152344	469.2410888671875	9.96258544921875	238.09512329101562	32
insurance, pension insurance, nursing insurance etc. or just	306.1417236328125	481.7132568359375	9.96258544921875	238.07427978515625	32
a part of these services.	306.1417236328125	494.1854248046875	9.96258544921875	95.4796142578125	32
There are also country-specific differences in patient care	317.48016357421875	506.600830078125	9.96258544921875	226.71099853515625	32
pathways, which are partly shaped by guidelines estab-	306.1417236328125	519.072998046875	9.96258544921875	238.06927490234375	32
lished by national medical associations or differently	306.1417236328125	531.545166015625	9.962615966796875	238.132080078125	32
organised educational systems for health care professionals.	306.1417236328125	543.9605712890625	9.962600708007812	238.0313720703125	32
Further limits on transferability can result from differences	306.1417236328125	556.4328002929688	9.962600708007812	238.088134765625	32
in the fundamental organisational principles of health care	306.1417236328125	568.9049682617188	9.962600708007812	238.0494384765625	32
systems (e.g. central vs decentralised planning). Other	306.1417236328125	581.3203735351562	9.962600708007812	238.07421875	32
potential problems when transferring the findings of	306.1417236328125	593.7925415039062	9.962600708007812	238.0504150390625	32
international studies to the national context can be	306.1417236328125	606.2647094726562	9.962600708007812	238.1649169921875	32
identified in a qualitative manner using checklists, such as	306.1417236328125	618.6801147460938	9.962600708007812	238.07720947265625	32
that provided in Table 1 (based on Heyland et al. 1996).	306.1417236328125	631.1522827148438	9.962600708007812	229.06805419921875	32
Approaches to the economic analysis of multinational	306.1417236328125	656.0398559570312	9.962600708007812	217.87408447265625	33
studies	306.1417236328125	668.5120239257812	9.962600708007812	27.36724853515625	33
In principle, there are various approaches to address the	306.1417236328125	693.4005737304688	9.962600708007812	238.0552978515625	34
question of heterogeneity of economic variables across	306.1417236328125	705.8727416992188	9.962600708007812	238.0135498046875	34
330	51.02360153198242	33.0572509765625	8.46820068359375	12.702301025390625	35
J Public Health (2010) 18:327–335	423.21197509765625	33.0572509765625	8.4737548828125	121.0418701171875	36
Table 1 Checklist for evaluating the transferability of findings from (multi)national studies to other countries (adapted from Heyland et al. 1996)	51.02360153198242	57.023193359375	8.4833984375	493.2328071594238	37
Transferability of clinical/epidemiological factors	51.023590087890625	75.86065673828125	8.46820068359375	168.11070251464844	38
Are there substantial differences between the populations eligible for recruitment to the study and the population of the country in question?	51.023590087890625	88.5595703125	8.46820068359375	483.5588073730469	38
Are the patients in the study comparable to those in the country in question?	51.023590087890625	101.25848388671875	8.46820068359375	264.61090087890625	38
Are there any regional differences in the incidence and prevalence of the disease analysed in the study?	51.023590087890625	113.9573974609375	8.46820068359375	357.2868957519531	38
In the event that preference-based outcomes (e.g. quality-of-life weights) are used in the study: have study investigators ensured that the	51.023590087890625	126.65631103515625	8.46820068359375	469.4913635253906	38
preferences of patients in the study are comparable to the preferences of the patients in the country in question?	51.023590087890625	136.6343994140625	8.46820068359375	385.59356689453125	38
[...]	51.023590087890625	149.33331298828125	8.46820068359375	11.804672241210938	38
Transferability of factors related to different health care systems	51.023590087890625	162.0322265625	8.46820068359375	219.8463134765625	38
Is/are the study intervention(s) comparable to the applicable medical intervention(s) provided in the country in question?	51.023590087890625	174.73114013671875	8.46820068359375	415.0747985839844	38
Are the costs of drugs, medical treatment, laboratory tests etc. comparable?	51.023590087890625	187.4300537109375	8.46820068359375	259.1361999511719	38
Are the types and amounts of resources used comparable?	51.023590087890625	200.12896728515625	8.46820068359375	200.23143005371094	38
Are accurate currency conversions possible between the different countries?	51.023590087890625	212.827880859375	8.46820068359375	260.7959899902344	38
Are the medical outcomes comparable to those observed in the health care system in question?	51.023590087890625	225.58355712890625	8.46820068359375	327.3136901855469	38
Are the discounting rates used in the study transferable to the country in question?	51.023590087890625	238.282470703125	8.46820068359375	285.0201110839844	38
[...]	51.023590087890625	250.98138427734375	8.46820068359375	11.804672241210938	38
countries in multinational studies. All methodologies aim to	51.02360153198242	294.232421875	9.96258544921875	238.06926345825195	39
translate real study data to an individual country. Under the	51.02360153198242	306.70458984375	9.96258544921875	238.05635452270508	39
reasonable assumption that internationally generated results	51.02360153198242	319.1199951171875	9.96258544921875	238.01948928833008	39
for the effectiveness of a treatment are less subject to	51.02360153198242	331.5921630859375	9.96258544921875	238.06721878051758	39
differences than cost results (Drummond and Pang 2001),	51.02360153198242	344.0643310546875	9.96258544921875	238.08223342895508	39
the focus of the following observations is on the adaptation	51.02362060546875	356.479736328125	9.96258544921875	238.08523559570312	39
of economic cost results.	51.02362060546875	368.951904296875	9.96258544921875	100.63119506835938	39
Provided that data are both available and accessible, in	62.362056732177734	381.424072265625	9.96258544921875	226.74277114868164	39
principal a bottom-up approach should be pursued where	51.02362060546875	393.8394775390625	9.96258544921875	238.14401245117188	39
individual data on resource consumption are the basis for both	51.02362060546875	406.3116455078125	9.96258544921875	238.08419799804688	39
individual cost calculation and a subsequent total cost	51.02362060546875	418.7838134765625	9.96258544921875	238.05734252929688	39
evaluation (Hay and Jackson 1999). This methodology has	51.02362060546875	431.19921875	9.96258544921875	238.08023071289062	39
the advantage that analysis of resource consumption can be	51.02461242675781	443.67138671875	9.96258544921875	238.13206481933594	39
made directly on the basis of the direct cost sets of a specific	51.02461242675781	456.0867919921875	9.96258544921875	238.12010192871094	39
country. This approach, however, requires detailed individual	51.02461242675781	468.5589599609375	9.96258544921875	238.1111602783203	39
data.	51.02461242675781	481.0311279296875	9.96258544921875	18.19568634033203	39
As shown in Fig. 1, the calculation of the cost-	62.3630485534668	493.446533203125	9.96258544921875	226.79756546020508	39
effectiveness of an intervention will be performed via the	51.02460479736328	505.918701171875	9.96258544921875	238.05733489990234	39
multinational study	130.05960083007812	543.4507446289062	9.28680419921875	76.90399169921875	40
consumption	91.14769744873047	580.4120483398438	9.28680419921875	52.646873474121094	41
of resources	93.22144317626953	591.5562133789062	9.28680419921875	51.095970153808594	41
costs	107.92639923095703	632.7592163085938	9.28680419921875	21.675392150878906	42
effectiveness	194.01499938964844	609.3562622070312	9.28680419921875	54.19776916503906	43
cost-effectiveness	131.32859802246094	673.4660034179688	9.286796569824219	74.32225036621094	44
costs/effectiveness outcomes	117.92489624023438	684.4024047851562	7.7389984130859375	101.06436157226562	44
Fig. 1 Determination of cost-effectiveness	51.02360153198242	707.06396484375	8.4833984375	146.74965286254883	45
combination of adapted cost results and (multi)national	306.1418762207031	294.2283935546875	9.96258544921875	237.99465942382812	46
effectiveness results.	306.1418762207031	306.7005615234375	9.96258544921875	82.71551513671875	46
Pooled/split analysis approach	306.1418762207031	331.588134765625	9.96258544921875	124.5743408203125	47
Based on this pattern, different sources can be identified to	306.1418762207031	356.4757080078125	9.96258544921875	238.06832885742188	48
analyse effectiveness and resource data within a multina-	306.1418762207031	368.9478759765625	9.96258544921875	238.06033325195312	48
tional study. In principle, different combinations are	306.1418762207031	381.4200439453125	9.96258544921875	238.04830932617188	48
conceivable which are shown in Fig. 2.	306.1418762207031	393.83544921875	9.96258544921875	159.98342895507812	48
A completely pooled analysis assumes that there are no	317.4813232421875	406.3076171875	9.96258544921875	226.8294677734375	48
restrictions with regard to the adaptation of multinational study	306.14288330078125	418.77978515625	9.96258544921875	238.0772705078125	48
results at the level of a specific country. Since this assumption is	306.14288330078125	431.1951904296875	9.96258544921875	238.0413818359375	48
not very likely as previously noted, the partially pooled,	306.14288330078125	443.6673583984375	9.96258544921875	238.1708984375	48
respectively split analysis gains more relevance.	306.14288330078125	456.082763671875	9.96258544921875	183.46823120117188	48
With this approach only data of a certain country	317.4813232421875	468.554931640625	9.96258544921875	226.79766845703125	48
selection (e.g. with comparable patient clientele and/or	306.14288330078125	481.027099609375	9.96258544921875	238.017578125	48
health care systems) or a single country concerned are	306.14288330078125	493.4425048828125	9.96258544921875	238.05926513671875	48
selected for further evaluation. These methodologies are	306.14288330078125	505.9146728515625	9.96258544921875	238.060302734375	48
easily comprehensible and thus a high transparency can be	306.14288330078125	518.3868408203125	9.96258544921875	238.08917236328125	48
achieved for the methods and presentation of results.	306.14288330078125	530.80224609375	9.962615966796875	214.14813232421875	48
However, a disadvantage of this approach is the reduced	317.4813232421875	543.2744140625	9.962600708007812	226.7906494140625	48
sample size, which, in a fully split analysis, can reduce the	306.14288330078125	555.7466430664062	9.962600708007812	238.1309814453125	48
significance of the results (Pinto et al. 2005; Reed et al. 2005).	306.14288330078125	568.1619873046875	9.962600708007812	238.10516357421875	48
In any case, these analytic approaches are only feasible when	306.14288330078125	580.6342163085938	9.962600708007812	238.12115478515625	48
the country of interest was involved in the study. Figure 3	306.14288330078125	593.1063842773438	9.962600708007812	238.1011962890625	48
summarises the fundamental problems of pooled and split	306.14288330078125	605.5217895507812	9.962600708007812	238.06439208984375	48
analyses.	306.14288330078125	617.9939575195312	9.962600708007812	34.520416259765625	48
In practice, there are often pooled/split analyses in which, on	317.4813232421875	630.4661254882812	9.962600708007812	226.76666259765625	48
the one hand, pooled effectiveness data of all participating	306.14288330078125	642.8815307617188	9.962600708007812	238.11505126953125	48
countries are taken into consideration, whereas, on the other	306.14288330078125	655.3536987304688	9.962608337402344	238.10211181640625	48
hand, only resource data of the country concerned are	306.14288330078125	667.8258666992188	9.962600708007812	238.11810302734375	48
considered. This approach is a trade-off between a country-	306.14288330078125	680.2412719726562	9.962600708007812	238.10504150390625	48
based assignment of resources and a high statistical power	306.14288330078125	692.7134399414062	9.962600708007812	238.114013671875	48
concerning the effectiveness data (Reed et al. 2005).	306.14288330078125	705.1856079101562	9.962600708007812	200.4046630859375	48
J Public Health (2010) 18:327–335	51.02360153198242	33.0572509765625	8.4737548828125	121.04190444946289	49
Fig. 2 Conceivable analysis	51.02360153198242	52.3743896484375	8.4833984375	110.5235481262207	50
methodologies/approaches for	51.023597717285156	62.36767578125	8.46820068359375	102.04096221923828	50
the determination of resources	51.023597717285156	72.28900146484375	8.46820068359375	103.60079193115234	50
and effectiveness data (our own	51.023597717285156	82.26708984375	8.46820068359375	109.2829818725586	50
representation)	51.023597717285156	92.24517822265625	8.46820068359375	50.038597106933594	50
a	189.87899780273438	112.895751953125	0.0	5.1318359375	51
t	189.87899780273438	115.47088623046875	0.0	2.56591796875	51
a	189.87899780273438	120.6119384765625	0.0	5.1318359375	51
d	189.87899780273438	125.75299072265625	0.0	5.1318359375	51
e	189.87899780273438	133.443359375	0.0	5.1318359375	51
c	189.87899780273438	138.0675048828125	0.0	4.61492919921875	51
r	189.87899780273438	141.15032958984375	0.0	3.07354736328125	51
u	189.87899780273438	146.2913818359375	0.0	5.1318359375	51
o	189.87899780273438	151.43243408203125	0.0	5.1318359375	51
s	189.87899780273438	156.05657958984375	0.0	4.61492919921875	51
e	189.87899780273438	161.19769287109375	0.0	5.1318359375	51
r	189.87899780273438	164.28045654296875	0.0	3.07354736328125	51
f	189.87899780273438	169.4049072265625	0.0	2.56591796875	51
o	189.87899780273438	174.54595947265625	0.0	5.1318359375	51
e	189.87899780273438	182.23626708984375	0.0	5.1318359375	51
c	189.87899780273438	186.8604736328125	0.0	4.61492919921875	51
r	189.87899780273438	189.9432373046875	0.0	3.07354736328125	51
u	189.87899780273438	195.08428955078125	0.0	5.1318359375	51
o	189.87899780273438	200.225341796875	0.0	5.1318359375	51
s	189.87899780273438	204.84954833984375	0.0	4.61492919921875	51
All participating	218.62905883789062	124.8841552734375	8.2296142578125	55.576141357421875	52
countries	218.62905883789062	134.760498046875	8.2296142578125	33.28546142578125	52
Sample of	218.62905883789062	161.34259033203125	8.2296142578125	37.00355529785156	53
countries	218.62905883789062	171.1785888671875	8.2296142578125	33.28546142578125	53
Single country	218.62905883789062	197.7613525390625	8.2296142578125	51.992156982421875	54
Statistical approaches	51.02360153198242	247.29071044921875	9.96258544921875	88.7149543762207	55
Since pooled/split analyses provide a compromise between	51.02360153198242	272.23504638671875	9.962615966796875	238.03639602661133	56
restriction-free transferability of the study results for a	51.02360153198242	284.6504821777344	9.96258544921875	238.0952033996582	56
certain country and a high statistical power, during the last	51.02360153198242	297.1226501464844	9.96258544921875	238.06926345825195	56
few years, statistical analyses have been developed to	51.02360153198242	309.5948181152344	9.96258544921875	238.06926345825195	56
approximate the optimal compromise. Among these,	51.02360153198242	322.0102233886719	9.96258544921875	238.07927322387695	56
regression-based approaches belong to the most frequently	51.02360153198242	334.4823913574219	9.96258544921875	238.08525466918945	56
common statistical methodologies. A potential disadvan-	51.02360153198242	346.9545593261719	9.96258544921875	238.05730056762695	56
tage of the statistical methods presented is, in part, the	51.02360153198242	359.3699645996094	9.96258544921875	238.05733108520508	56
complexity of the approach which involves again a reduced	51.02360153198242	371.8421325683594	9.96258544921875	238.02443313598633	56
transparency, and thus reduces the potential use as a	51.02360153198242	384.3143005371094	9.96258544921875	238.1010627746582	56
decision making aid (Reed et al. 2005).	51.02360153198242	396.7297058105469	9.96258544921875	160.41279983520508	56
Hence, a study published by Koopmanschap et al.	62.362030029296875	409.2018737792969	9.96258544921875	226.77664184570312	56
recommends the use of multivariate regression analyses.	51.02359390258789	421.6740417480469	9.96258544921875	238.15493392944336	56
This is proposed in order to quantify and adjust differ-	51.02359390258789	434.0894470214844	9.96258544921875	238.0652732849121	56
ences in resource consumption and costs in multinational	51.02359390258789	446.5616149902344	9.96258544921875	238.08123397827148	56
studies in a way such that the studies would have been	51.02359390258789	459.0337829589844	9.96258544921875	238.1071434020996	56
carried out in only one country (Koopmanschap et al.	51.02359390258789	471.4491882324219	9.96258544921875	238.12609481811523	56
2001). Herewith two options were pursued. A first	51.02359390258789	483.9213562011719	9.96258544921875	238.05532455444336	56
approach uses the identification of the differences in the	51.023590087890625	496.3367614746094	9.96258544921875	238.12109375	56
331	531.5515747070312	33.0572509765625	8.46820068359375	12.7022705078125	57
source of effectiveness data	362.6097106933594	56.543701171875	9.22991943359375	115.09317016601562	58
All participating	300.92999267578125	89.82440185546875	8.2296142578125	55.576141357421875	59
countries	300.92999267578125	99.70074462890625	8.2296142578125	33.286285400390625	59
fully pooled	300.92999267578125	124.8841552734375	8.2296142578125	41.42120361328125	60
analysis	300.92999267578125	134.760498046875	8.2296142578125	29.624114990234375	60
partially pooled	300.92999267578125	161.34259033203125	8.2296142578125	55.08563232421875	61
analysis	300.92999267578125	171.1785888671875	8.2296142578125	29.624114990234375	61
Sample of	383.2309265136719	89.82440185546875	8.2296142578125	37.00274658203125	62
countries	383.2309265136719	99.70074462890625	8.2296142578125	33.28546142578125	62
partially pooled	383.2305908203125	124.8841552734375	8.2296142578125	55.084808349609375	63
analysis	383.2305908203125	134.760498046875	8.2296142578125	29.610107421875	63
Single country	465.5318603515625	89.82440185546875	8.2296142578125	51.95843505859375	64
partially pooled/split	465.5310974121094	124.8841552734375	8.2296142578125	71.96536254882812	65
analysis	465.5310974121094	134.760498046875	8.2296142578125	29.62493896484375	65
partially pooled/split	383.2305908203125	161.34259033203125	8.2296142578125	72.0	66
analysis	383.2305908203125	171.1785888671875	8.2296142578125	29.610107421875	66
partially split	465.5310974121094	161.34259033203125	8.2296142578125	45.057098388671875	67
analysis	465.5310974121094	171.1785888671875	8.2296142578125	29.62493896484375	67
partially pooled/split	300.92999267578125	197.7613525390625	8.2296142578125	72.0	68
analysis	300.92999267578125	207.6376953125	8.2296142578125	29.624114990234375	68
partially split	383.2305908203125	197.7613525390625	8.2296142578125	45.063629150390625	69
analysis	383.2305908203125	207.6376953125	8.2296142578125	29.610107421875	69
fully split analysis	465.5310974121094	197.7613525390625	8.2296142578125	63.352325439453125	70
treatment samples and the associated consumption of	306.140869140625	247.28570556640625	9.96258544921875	238.059326171875	71
resources of the countries involved in order to form	306.140869140625	259.75787353515625	9.96258544921875	238.09716796875	71
homogeneous patient groups afterwards as precisely as	306.140869140625	272.23004150390625	9.96258544921875	238.13201904296875	71
possible. For all groups of resources, statistically significant	306.140869140625	284.64544677734375	9.96258544921875	238.184814453125	71
and relevant country differences are determined, which are	306.140869140625	297.11761474609375	9.96258544921875	238.09918212890625	71
then subject to further correction. For example if in a country	306.140869140625	309.58978271484375	9.96258544921875	238.1041259765625	71
×% less laboratory tests are carried out (with consideration of	306.140869140625	322.00518798828125	9.96258544921875	238.080078125	71
possible differences in the patient characteristics), the	306.140869140625	334.47735595703125	9.96258544921875	238.0732421875	71
number of laboratory tests of the patients of other	306.140869140625	346.94952392578125	9.96258544921875	238.09820556640625	71
countries should be corrected downward by this factor ×.	306.140869140625	359.36492919921875	9.96258544921875	238.1668701171875	71
The corrected resource utilisations are then multiplied by a	306.140869140625	371.83709716796875	9.96258544921875	238.05224609375	71
country-specific cost set.	306.140869140625	384.30926513671875	9.96258544921875	102.21429443359375	71
A second approach tries to identify a possible country-	317.47930908203125	396.72467041015625	9.96258544921875	226.7457275390625	71
specific influence directly at a cost expense level. In a	306.140869140625	409.19683837890625	9.96258544921875	238.09722900390625	71
multivariate regression analysis, the influence of different	306.140869140625	421.66900634765625	9.96258544921875	238.0731201171875	71
covariates (beside the country of the study, e.g. the age of the	306.140869140625	434.08441162109375	9.96258544921875	238.135986328125	71
study participants and the disease status) on certain expenses is	306.140869140625	446.55657958984375	9.96258544921875	238.1109619140625	71
examined. A limitation of the proceedings represented by	306.140869140625	459.02874755859375	9.96258544921875	238.15704345703125	71
Koopmanschap et al. arises because of the isolated focus on	306.140869140625	471.44415283203125	9.96258544921875	238.105224609375	71
resources and/or expenses, with which possible country-	306.140869140625	483.91632080078125	9.96258544921875	238.19189453125	71
specific effectiveness differences remain unconsidered.	306.140869140625	496.33172607421875	9.96258544921875	209.758544921875	71
source of effectiveness data	299.95849609375	527.5711059570312	9.25	115.34381103515625	72
a	124.59169006347656	583.3150634765625	0.0	5.14300537109375	73
t	124.59169006347656	585.8958129882812	0.0	2.571502685546875	73
a	124.59169006347656	591.048095703125	0.0	5.14300537109375	73
d	124.59169006347656	596.2003173828125	0.0	5.14300537109375	73
e	124.59169006347656	603.907470703125	0.0	5.14300537109375	73
c	124.59169006347656	608.5416870117188	0.0	4.625	73
r	124.59169006347656	611.6311645507812	0.0	3.0802459716796875	73
u	124.59169006347656	616.783447265625	0.0	5.14300537109375	73
o	124.59169006347656	621.9356689453125	0.0	5.14300537109375	73
s	124.59169006347656	626.5699462890625	0.0	4.625	73
e	124.59169006347656	631.72216796875	0.0	5.14300537109375	73
r	124.59169006347656	634.8116455078125	0.0	3.0802459716796875	73
f	124.59169006347656	639.947265625	0.0	2.571502685546875	73
o	124.59169006347656	645.0995483398438	0.0	5.14300537109375	73
e	124.59169006347656	652.806640625	0.0	5.14300537109375	73
c	124.59169006347656	657.44091796875	0.0	4.625	73
r	124.59169006347656	660.5303955078125	0.0	3.0802459716796875	73
u	124.59169006347656	665.6826171875	0.0	5.14300537109375	73
o	124.59169006347656	670.8348999023438	0.0	5.142997741699219	73
s	124.59169006347656	675.4691162109375	0.0	4.625	73
All participating	154.66949462890625	595.0953979492188	8.24749755859375	55.69703674316406	74
countries	154.66949462890625	604.9940795898438	8.24749755859375	33.35783386230469	74
Sample of	154.66949462890625	631.6340942382812	8.24749755859375	37.089019775390625	75
countries	154.66949462890625	641.4915161132812	8.247512817382812	33.35783386230469	75
Single country	154.66949462890625	662.8109130859375	8.247505187988281	52.10523986816406	76
All participating	237.1502685546875	559.9585571289062	8.247512817382812	55.696197509765625	77
countries	237.1502685546875	569.8572387695312	8.247512817382812	33.357818603515625	77
Sample of	319.6302185058594	559.9585571289062	8.247512817382812	37.089019775390625	78
countries	319.6302185058594	569.8572387695312	8.247512817382812	33.357818603515625	78
Single country	402.11016845703125	559.9585571289062	8.247512817382812	52.0714111328125	79
decreasing transferability to a	281.35791015625	613.2407836914062	8.247512817382812	107.52841186523438	80
single country	284.2445373535156	623.0973510742188	8.24749755859375	50.6561279296875	80
increasing statistical power	281.35791015625	632.9951782226562	8.24749755859375	98.23187255859375	80
increasing transferability to a	300.864990234375	648.2949829101562	8.247512817382812	104.7828369140625	81
single country	303.7516174316406	658.1515502929688	8.24749755859375	50.676788330078125	81
decreasing statistical power	300.864990234375	668.048583984375	8.24749755859375	100.9501953125	81
Fig. 3 Fundamental limitations of pooled/split analyses (our own representation)	51.02360153198242	706.6671752929688	8.4833984375	278.7943000793457	82
332	51.02360153198242	33.0572509765625	8.46820068359375	12.702301025390625	83
Other authors try to get around this limitation. In a	62.36220169067383	58.333251953125	9.96258544921875	226.75779342651367	84
publication of Willke et al. (1998) the attempt is undertaken	51.023765563964844	70.7486572265625	9.96258544921875	238.07022857666016	84
to identify both country-specific differences in effectiveness	51.02375793457031	83.2208251953125	9.96258544921875	238.05531311035156	84
and the quantification of differences in resources and cost.	51.02375793457031	95.6929931640625	9.96258544921875	238.0324249267578	84
The statistical methodology assumes that a number of	51.02375793457031	108.1083984375	9.96258544921875	238.0771942138672	84
exogenous variables (e.g. disease stage), therapy outcomes	51.02375793457031	120.58056640625	9.96258544921875	238.02943420410156	84
as well as the interaction of country-specific treatment and	51.02375793457031	133.052734375	9.96258544921875	238.08226013183594	84
country-specific outcomes per se influence costs of a	51.02375793457031	145.4681396484375	9.96258544921875	238.1141815185547	84
treatment of an individual patient by treatment. The	51.02375793457031	157.9403076171875	9.96258544921875	238.07725524902344	84
proposal described by these authors considered also	51.02375793457031	170.4124755859375	9.96258544921875	238.1449737548828	84
country-specific outcome differences and thus partially	51.02375030517578	182.827880859375	9.96258544921875	238.03841400146484	84
goes beyond existing recommendations [e.g. Ontario	51.02375030517578	195.300048828125	9.96258544921875	238.12203216552734	84
Guidelines for Economic Analysis of Pharmaceutical	51.02375030517578	207.772216796875	9.96258544921875	238.05236053466797	84
Products (Ontario Ministry of Health and Long-Term Care	51.02375030517578	220.1876220703125	9.96258544921875	238.06230926513672	84
1994)] for the adaptation of multinational studies, because	51.02375030517578	232.6597900390625	9.96258544921875	238.02645111083984	84
frequently only the consideration of possible country-	51.02375030517578	245.1319580078125	9.96258544921875	238.0702133178711	84
specific cost and/or resource differences is required.	51.02375030517578	257.54736328125	9.96258544921875	210.28160858154297	84
Besides these statistical proposals, further statistical	62.362186431884766	270.01953125	9.96258544921875	226.75573348999023	84
approaches have been generated in recent years (Cook et	51.02375030517578	282.49169921875	9.96258544921875	238.06331634521484	84
al. 2003; Grieve et al. 2005; Pinto et al. 2005; Thompson et	51.02375030517578	294.9071044921875	9.96258544921875	238.0663070678711	84
al. 2006; Willan et al. 2005).	51.02473449707031	307.3792724609375	9.96258544921875	117.49790954589844	84
Modelling of long-term costs and outcomes	51.025733947753906	332.266845703125	9.96258544921875	175.94152069091797	85
In many situations the use of decision analytic models is	51.025733947753906	357.1544189453125	9.96258544921875	238.05632781982422	86
preferred because it frequently occurs that there are no	51.025733947753906	369.6265869140625	9.96258544921875	238.09221649169922	86
patient-based data available from the participating centres	51.025733947753906	382.0987548828125	9.96258544921875	238.07027435302734	86
in the study or that the country of interest did not participate	51.025733947753906	394.51416015625	9.96258544921875	238.06127166748047	86
in the study (Drummond et al. 1997). So-called modelling	51.025733947753906	406.986328125	9.96258544921875	238.08721160888672	86
studies enable the adaptation of treatment effects identified	51.02674865722656	419.45849609375	9.96258544921875	238.0583038330078	86
at the study level to different populations and health care	51.02674865722656	431.8739013671875	9.96258544921875	238.04734802246094	86
systems. Often clinical studies are carried out without	51.02674865722656	444.3460693359375	9.96258544921875	238.07823181152344	86
accompanying collection of economic parameters. An	51.02674865722656	456.8182373046875	9.96258544921875	238.10914611816406	86
advantage, which the health economic modelling can offer,	51.02674865722656	469.233642578125	9.96258544921875	238.1031036376953	86
is the possibility of using and combining data from different	51.02674865722656	481.705810546875	9.96258544921875	238.1061248779297	86
sources.	51.02674865722656	494.177978515625	9.96258544921875	32.12141418457031	86
For example decision analytic models are nowadays	62.36518478393555	506.5933837890625	9.96258544921875	226.72185134887695	86
used to adjust study data to the real routine supply or to	51.02674865722656	519.0655517578125	9.96258544921875	238.0683135986328	86
transfer study results to a country which did not participate	51.02674865722656	531.5377197265625	9.962615966796875	238.05931091308594	86
in the study. An example of this approach is described in	51.02674865722656	543.953125	9.962600708007812	238.06822204589844	86
the work of Menzin et al. (1996). The authors use a	51.02674865722656	556.4253540039062	9.962600708007812	238.09815979003906	86
decision analytic model alongside the data of a phase III	51.02674865722656	568.8975219726562	9.962600708007812	238.03736877441406	86
study in the USA for adaptation to the European context	51.02674865722656	581.3129272460938	9.962600708007812	238.0742645263672	86
(France, Italy and Germany).	51.02674865722656	593.7850952148438	9.962600708007812	117.29167175292969	86
A further type of application of decision analytic	62.36518478393555	606.2572631835938	9.962600708007812	226.76472854614258	86
models exists in the health economic analysis of clinical	51.02674865722656	618.6726684570312	9.962600708007812	237.9955291748047	86
studies, during which economic parameters were not	51.02674865722656	631.1448364257812	9.962600708007812	238.04539489746094	86
collected or were not available. Based on available study	51.02674865722656	643.6170043945312	9.962600708007812	238.0922393798828	86
information (e.g. characteristics of patient clientele,	51.02674865722656	656.0324096679688	9.962600708007812	238.1260528564453	86
clinical processes, event rates etc.) resulting resource	51.02674865722656	668.5045776367188	9.962600708007812	238.15696716308594	86
consumption is identified, on which basis a cost	51.02674865722656	680.9767456054688	9.962600708007812	238.0762176513672	86
evaluation of the study process could be performed. Via	51.02674865722656	693.3921508789062	9.962600708007812	238.15293884277344	86
extrapolation, an analysis of long-term costs of inter-	51.02674865722656	705.8643188476562	9.962600708007812	238.1628875732422	86
J Public Health (2010) 18:327–335	423.21197509765625	33.0572509765625	8.4737548828125	121.0418701171875	87
ventions or savings due to prevention of events is	306.14404296875	58.32025146484375	9.96258544921875	238.0931396484375	88
feasible (Siebert 2003).	306.14404296875	70.73565673828125	9.96258544921875	97.39340209960938	88
According to the IQWiG guidelines, the use of a	317.48248291015625	83.20782470703125	9.96258544921875	226.75872802734375	88
model for the economic evaluation of interventions must	306.14404296875	95.67999267578125	9.96258544921875	238.107177734375	88
be sufficiently justified (Bastian et al. 2006). In addition,	306.14404296875	108.09539794921875	9.96258544921875	238.1290283203125	88
a model must meet numerous quality standards. Thus,	306.14404296875	120.56756591796875	9.96258544921875	238.14208984375	88
decision models must be described transparently and	306.14404296875	133.03973388671875	9.96258544921875	238.18597412109375	88
comprehensibly and all assumptions must be explained.	306.14404296875	145.45513916015625	9.96258544921875	238.187744140625	88
Likewise, there is a demand for the implementation of	306.14404296875	157.92730712890625	9.96258544921875	238.08013916015625	88
sensitivity analyses along with a fully probabilistic	306.14404296875	170.39947509765625	9.96258544921875	238.18780517578125	88
approach.	306.14404296875	182.81488037109375	9.96258544921875	39.570465087890625	88
Furthermore, decision models should be subject to	317.48248291015625	195.28704833984375	9.96258544921875	226.79852294921875	88
validation. The mathematical computations must be vali-	306.14404296875	207.75921630859375	9.96258544921875	238.05828857421875	88
dated for their consistency with the model specifications,	306.14404296875	220.17462158203125	9.96258544921875	238.1041259765625	88
and it must be guaranteed that model input data and the	306.14404296875	232.64678955078125	9.96258544921875	238.05731201171875	88
outcomes are consistent with the available data. If different	306.14404296875	245.11895751953125	9.96258544921875	238.10516357421875	88
models come to different statements on the same questions,	306.14404296875	257.53436279296875	9.96258544921875	238.10211181640625	88
this identifies the necessity for a cross-validation of results	306.14404296875	270.00653076171875	9.96258544921875	238.0194091796875	88
(Bastian et al. 2006).	306.14404296875	282.47869873046875	9.96258544921875	85.01187133789062	88
Provided that the appropriate quality criteria have been	317.48248291015625	294.89410400390625	9.96258544921875	226.7298583984375	88
considered, the methodology of current health economic	306.14404296875	307.36627197265625	9.96258544921875	238.0753173828125	88
modelling is well established as a subsequent analysis of	306.14404296875	319.83843994140625	9.96258544921875	238.07525634765625	88
study data (Sculpher et al. 2004). Most international	306.14404296875	332.25384521484375	9.96258544921875	238.1151123046875	88
guidelines accept modelling in health economic evaluation	306.14404296875	344.72601318359375	9.96258544921875	238.085205078125	88
(Hjelmgren et al. 2001; Schöffski and Graf von der	306.14404296875	357.14141845703125	9.96258544921875	238.07623291015625	88
Schulenburg 2007), although there remains some scepti-	306.1440734863281	369.61358642578125	9.96258544921875	238.02835083007812	88
cism regarding the appropriateness of different modelling	306.1440734863281	382.08575439453125	9.96258544921875	238.08523559570312	88
approaches, especially where these appear to translate	306.1440734863281	394.50115966796875	9.96258544921875	238.10043334960938	88
unimpressive clinical effects into highly cost-effective	306.1440734863281	406.97332763671875	9.96258544921875	238.03640747070312	88
outcomes.	306.1440734863281	419.44549560546875	9.96258544921875	40.443206787109375	88
Transfer of data to a national setting	306.1440734863281	444.3340759277344	9.96258544921875	150.41537475585938	89
One approach which uses some elements of modelling	306.1440734863281	469.22265625	9.96258544921875	238.15402221679688	90
but adopts the efficacy of one single study of interest—	306.1440734863281	481.69482421875	9.99017333984375	238.09243774414062	90
possibly the pivotal key study on which registration was	306.142333984375	494.18798828125	9.96258544921875	238.1180419921875	90
based—is to transfer data of a multinational trial to an	306.142333984375	506.6033935546875	9.96917724609375	238.104248046875	90
existing national data set. A key focus of this approach is	306.142333984375	519.0755615234375	9.96258544921875	238.0960693359375	90
the linkage of patient data of the multinational study	306.142333984375	531.5477294921875	9.962615966796875	238.08331298828125	90
with patient data from national data based on specific	306.142333984375	543.963134765625	9.962600708007812	238.0662841796875	90
patient characteristics (e.g. age, sex, insurance status,	306.142333984375	556.4353637695312	9.962600708007812	238.1510009765625	90
ICD diagnoses etc.). An important prerequisite for the	306.142333984375	568.9075317382812	9.962600708007812	238.09808349609375	90
practical implementation of the matching process is	306.142333984375	581.3229370117188	9.962600708007812	238.10516357421875	90
therefore the existence of matching variables on the	306.142333984375	593.7951049804688	9.962600708007812	238.1480712890625	90
patient level. If an international study delivers patient-	306.142333984375	606.2672729492188	9.962600708007812	238.11505126953125	90
level information only on sociodemography and therapy	306.142333984375	618.6826782226562	9.962600708007812	238.107177734375	90
effectiveness, economic data of comparable patients from	306.142333984375	631.1548461914062	9.962600708007812	238.1270751953125	90
national databases can be assigned by means of patient	306.142333984375	643.6270141601562	9.962600708007812	238.13800048828125	90
matching. Important, however, is the selection of relevant	306.142333984375	656.0424194335938	9.962600708007812	238.08428955078125	90
matching variables such as age, sex, disease stages etc.	306.142333984375	668.5145874023438	9.962600708007812	238.14300537109375	90
In a following step, differences of effectiveness between	306.142333984375	680.9867553710938	9.962600708007812	238.156982421875	90
the treatment arms are extracted and assessed according	306.142333984375	693.4021606445312	9.962600708007812	238.11114501953125	90
to the national cost schedule (e.g. the group difference	306.142333984375	705.8743286132812	9.962600708007812	238.10614013671875	90
J Public Health (2010) 18:327–335	51.02360153198242	33.0572509765625	8.4737548828125	121.04190444946289	91
concerning cardiac events in studies with cardiovascular	51.02360153198242	58.333251953125	9.96258544921875	238.11409378051758	92
background).	51.02360153198242	70.7486572265625	9.96258544921875	53.68545913696289	92
As a result, assessment of national cost-effectiveness can	62.362037658691406	83.2208251953125	9.96258544921875	226.7636947631836	92
be obtained by matching available patient characteristics	51.02360153198242	95.6929931640625	9.96258544921875	238.08916091918945	92
from the international trial with the national cost compo-	51.02360153198242	108.1083984375	9.96258544921875	238.1917610168457	92
nents. A problem is that the fundamental goal of clinical	51.02360153198242	120.58056640625	9.96258544921875	238.18080520629883	92
studies is the proof of the effectiveness of an intervention	51.02360153198242	133.052734375	9.96258544921875	238.2087287902832	92
under controlled conditions (efficacy). Therefore, the	51.02360153198242	145.4681396484375	9.96258544921875	238.0772590637207	92
collection of economic parameters in such studies is	51.02360153198242	157.9403076171875	9.96258544921875	238.0703010559082	92
often of less relevance. The matching process illustrated	51.02360153198242	170.4124755859375	9.96258544921875	238.13502883911133	92
so far would therefore only reflect the cost-effectiveness	51.02360153198242	182.827880859375	9.96258544921875	238.0334358215332	92
at the time of the execution of the clinical study in the	51.02360534667969	195.300048828125	9.96258544921875	238.1190948486328	92
country concerned (dependence on the related matching	51.02360534667969	207.772216796875	9.96258544921875	238.0872039794922	92
database).	51.02360534667969	220.1876220703125	9.96258544921875	40.562721252441406	92
A transfer of the cost-effectiveness results to the current	62.36204147338867	232.6597900390625	9.96258544921875	226.72090530395508	92
real life setting would be achieved by incorporating data	51.02360534667969	245.1319580078125	9.96258544921875	238.0453643798828	92
from national data sources (e.g. health insurance data). The	51.02360534667969	257.54736328125	9.96258544921875	238.0982208251953	92
integration of data from automated databases or health	51.02360534667969	270.01953125	9.96258544921875	238.06333923339844	92
service research offers the potential to illustrate current	51.02360534667969	282.49169921875	9.96258544921875	238.06529235839844	92
consumption of resources and/or the costs of treatment in	51.02360534667969	294.9071044921875	9.96258544921875	238.0673065185547	92
everyday life. Owing to specific characteristics of the	51.02360534667969	307.3792724609375	9.96258544921875	238.0563507080078	92
German health system, this approach could realise both	51.02360534667969	319.8514404296875	9.96258544921875	238.0523223876953	92
the adaptation to the national context and the consideration	51.02360534667969	332.266845703125	9.96258544921875	238.0333709716797	92
of real health care conditions.	51.02360534667969	344.739013671875	9.96258544921875	120.22068786621094	92
333	531.5515747070312	33.0572509765625	8.46820068359375	12.7022705078125	93
Recommended analytic methods	306.140869140625	58.3272705078125	9.96258544921875	130.80294799804688	94
Based on the analytic methods described above, a number	306.140869140625	83.2158203125	9.96258544921875	238.084228515625	95
of recommendations can be made as to which method	306.140869140625	95.68798828125	9.96258544921875	238.08624267578125	95
applies best to which situation. These recommendations are	306.140869140625	108.1033935546875	9.96258544921875	238.061279296875	95
summarised in a flow chart shown in Fig. 4. However, these	306.140869140625	120.5755615234375	9.96258544921875	238.0284423828125	95
recommendations cover a restricted range of scenarios only.	306.141845703125	133.0477294921875	9.96258544921875	238.10321044921875	95
Indeed, it is very plausible that there are situations in which	306.141845703125	145.463134765625	9.96258544921875	238.0592041015625	95
a method different from those described would be more	306.141845703125	157.935302734375	9.96258544921875	238.02447509765625	95
appropriate.	306.141845703125	170.407470703125	9.96258544921875	47.3612060546875	95
Discussion	306.141845703125	207.75030517578125	9.962646484375	44.465057373046875	96
As the importance of health economic evaluations has grown,	306.141845703125	232.65576171875	9.96258544921875	238.2139892578125	97
so has the number of methodological tools available. Today,	306.141845703125	245.1279296875	9.96258544921875	238.10418701171875	97
broad ranges of approaches are used for the economic analysis	306.141845703125	257.5433349609375	9.96258544921875	238.1748046875	97
of data from multinational studies, including study-based	306.141845703125	270.0155029296875	9.96258544921875	238.10137939453125	97
techniques, statistical methods and modelling. Despite this,	306.141845703125	282.4876708984375	9.96258544921875	238.10235595703125	97
none of the approaches described above is free of limitations.	306.141845703125	294.903076171875	9.96258544921875	238.106201171875	97
Finally, choosing a particular method always involves a	306.141845703125	307.375244140625	9.96258544921875	238.09625244140625	97
balancing act between methodological transparency, statistical	306.141845703125	319.847412109375	9.96258544921875	238.075439453125	97
power and the transferability of results from multinational	306.141845703125	332.2628173828125	9.96258544921875	238.1788330078125	97
studies to different settings.	306.141845703125	344.7349853515625	9.96258544921875	106.974365234375	97
pooled/split	93.61914825439453	601.9637451171875	8.350509643554688	41.95207977294922	98
analyses	96.54265594482422	611.9634399414062	8.350509643554688	32.708900451660156	98
statistical	93.61497497558594	631.9637451171875	8.350509643554688	34.205322265625	99
approaches	96.54265594482422	641.9634399414062	8.350509643554688	43.255592346191406	99
data-transfer to a	93.61914825439453	661.9620971679688	8.350502014160156	63.04962921142578	100
national setting	96.54265594482422	671.9617919921875	8.350502014160156	55.69867706298828	100
Was the country of interest a part of	231.6407012939453	378.6673278808594	8.350494384765625	131.24473571777344	101
the multinational study?	253.74029541015625	388.66705322265625	8.350494384765625	86.96209716796875	101
yes	278.28948974609375	417.7164306640625	8.350494384765625	12.92657470703125	102
no	303.28753662109375	417.7164306640625	8.350494384765625	9.192230224609375	103
Are patient-level data	182.5408935546875	487.3153381347656	8.350494384765625	78.20492553710938	104
accessible?	199.94082641601562	497.3150634765625	8.350494384765625	43.418426513671875	104
yes	202.64141845703125	512.215087890625	8.350494384765625	12.916549682617188	105
no	227.6394805908203	512.215087890625	8.350494384765625	9.193069458007812	106
Are patient-level data	328.98919677734375	487.3153381347656	8.350494384765625	78.23504638671875	107
accessible?	346.3891296386719	497.3150634765625	8.350494384765625	43.41839599609375	107
yes	349.13592529296875	512.215087890625	8.350494384765625	12.91656494140625	108
no	374.1306457519531	512.215087890625	8.350494384765625	9.19305419921875	109
decision-modeling	197.56692504882812	601.9637451171875	8.350509643554688	66.93344116210938	110
decision-modeling	424.31463623046875	601.9637451171875	8.350509643554688	66.9317626953125	111
decision-modeling	315.6653137207031	601.9637451171875	8.350509643554688	66.93255615234375	112
data-transfer to a	315.6653137207031	621.9640502929688	8.350509643554688	63.049652099609375	113
national setting	318.5879821777344	631.9637451171875	8.350509643554688	55.676116943359375	113
Fig. 4 Recommendations for selected methods to analyse multinational studies	51.02360153198242	706.7805786132812	8.4833984375	272.9377021789551	114
334	51.02360153198242	33.0572509765625	8.46820068359375	12.702301025390625	115
Inevitably, making decisions about the value of	62.36220169067383	58.333251953125	9.96258544921875	226.71787643432617	116
pharmaceuticals in any context requires the combination	51.023765563964844	70.7486572265625	9.96258544921875	238.13001251220703	116
of data from different sources—this either can happen in	51.023765563964844	83.2208251953125	9.96917724609375	238.13501739501953	116
a qualitative way through expert judgement or can be	51.02275085449219	95.6929931640625	9.96258544921875	238.12208557128906	116
addressed by means of some form of modelling scenario.	51.02275085449219	108.1083984375	9.96258544921875	238.1399688720703	116
Such economic models have potential strengths and	51.02275085449219	120.58056640625	9.96258544921875	238.0682830810547	116
challenges. The greatest potential strength is in fully	51.02275085449219	133.052734375	9.96258544921875	238.0980987548828	116
probabilistic modelling, which may provide appropriate	51.02275085449219	145.4681396484375	9.96258544921875	238.01148986816406	116
estimates of cost-effectiveness in different circumstances,	51.02275085449219	157.9403076171875	9.96258544921875	238.0991973876953	116
which may be specified by the modeller. The updated	51.02275848388672	170.4124755859375	9.96258544921875	238.19873809814453	116
British NICE guide on the methods of technology	51.02275848388672	182.827880859375	9.96258544921875	238.0921401977539	116
appraisal also recommended this approach (Claxton et	51.02275848388672	195.300048828125	9.96258544921875	238.0573501586914	116
al. 2005). The greatest challenge is to avoid the situation	51.02275848388672	207.772216796875	9.96258544921875	238.12604522705078	116
where the design and population of economic models is	51.02275848388672	220.1876220703125	9.96258544921875	238.1231460571289	116
undertaken with a particular aim and without objective use	51.02275848388672	232.6597900390625	9.96258544921875	238.12012481689453	116
of available data.	51.02275848388672	245.1319580078125	9.96258544921875	70.75238800048828	116
The importance of country-specific evaluations of	62.3611946105957	257.54736328125	9.96258544921875	226.77866744995117	116
effectiveness and, in particular, of economic data (e.g.	51.02275848388672	270.01953125	9.96258544921875	238.17292022705078	116
costs and cost-effectiveness) is something that needs to	51.02275848388672	282.49169921875	9.96258544921875	238.1818618774414	116
be considered even in the earliest phases of study	51.02275848388672	294.9071044921875	9.96258544921875	238.09220123291016	116
development. Indeed, the timely documentation of	51.02275848388672	307.3792724609375	9.96258544921875	238.08917999267578	116
potential country-specific differences can simplify the	51.02275848388672	319.8514404296875	9.96258544921875	238.16693878173828	116
later analysis and interpretation of study findings.	51.02275848388672	332.266845703125	9.96258544921875	238.07425689697266	116
Nevertheless, it would seem highly desirable to place	51.02276611328125	344.739013671875	9.96258544921875	238.06924438476562	116
the available methods within a firm and binding framework—	51.02276611328125	357.1544189453125	9.96917724609375	238.09417724609375	116
for example by establishing binding national and international	51.02278137207031	369.6265869140625	9.96258544921875	238.1768341064453	116
guidelines.	51.02278137207031	382.0987548828125	9.96258544921875	42.213523864746094	116
Conclusion	51.02278137207031	419.441650390625	9.96258544921875	47.279502868652344	117
The technical problems surrounding the health economic	51.02278137207031	444.34808349609375	9.96258544921875	238.0682830810547	118
assessments and adaptations based on multinational	51.02278137207031	456.82025146484375	9.96258544921875	238.0583038330078	118
studies are well known and generally accepted. From	51.02278137207031	469.23565673828125	9.96258544921875	238.07029724121094	118
the perspective of national decision makers, there is	51.02278137207031	481.70782470703125	9.96258544921875	238.1180877685547	118
nevertheless a great need to adapt the findings of these	51.02278137207031	494.17999267578125	9.96258544921875	238.1320343017578	118
studies to the local setting, especially in light of their	51.02278137207031	506.59539794921875	9.96258544921875	237.99855041503906	118
economic impact. There are a variety of methods for	51.02278137207031	519.0675659179688	9.96258544921875	238.0891876220703	118
identifying and adjusting country-specific differences in	51.02278137207031	531.5396728515625	9.962615966796875	238.0623016357422	118
costs, effects and cost-effectiveness. As a result, multi-	51.02278137207031	543.9551391601562	9.962600708007812	238.0573272705078	118
national studies will continue to play a crucial role in the	51.02278137207031	556.4273071289062	9.962600708007812	238.16395568847656	118
evaluation of cost-effectiveness at the national level. It	51.02278137207031	568.8995361328125	9.962600708007812	238.1310577392578	118
seems likely that the growing interest in multinational	51.02278137207031	581.3148803710938	9.962600708007812	238.09019470214844	118
studies will lead to continued developments in adaptation	51.02278137207031	593.787109375	9.962600708007812	238.0872039794922	118
methods, thus helping to ensure the consistency and	51.02278137207031	606.25927734375	9.962600708007812	238.14601135253906	118
transferability of study findings between various settings.	51.02278137207031	618.6746826171875	9.962600708007812	238.10118103027344	118
Acknowledgments We would like to thank Sanofis-Aventis Germany	51.02360153198242	656.2671508789062	8.4833984375	238.0843391418457	119
GmbH for supporting this investigation by a non-restrictive research	51.023597717285156	666.2604370117188	8.46820068359375	238.06566619873047	119
contribution.	51.023597717285156	676.1817626953125	8.46820068359375	40.99201965332031	119
Conflict of interest The authors confirm that there are no relevant	51.023597717285156	696.1227416992188	8.4833984375	238.0512924194336	120
associations that might pose a conflict of interest.	51.02360534667969	706.0592651367188	8.46820068359375	170.37171936035156	120
J Public Health (2010) 18:327–335	423.21197509765625	33.0572509765625	8.4737548828125	121.0418701171875	121
References	306.1416931152344	58.31536865234375	9.962646484375	45.8179931640625	122
<ref>Asplund K, Ashburner S, Cargill K, Hux M, Lees K, Drummond M,	306.1416931152344	88.38958740234375	8.46820068359375	238.08432006835938	123
et al (2003) Health care resource use and stroke outcome.	323.0924987792969	98.36767578125	8.46820068359375	221.11996459960938	123
Multinational comparisons within the GAIN International trial.	323.0924987792969	108.34576416015625	8.46820068359375	221.14291381835938	123
Int J Technol Assess Health Care 19(2):267–277</ref>	323.0924987792969	118.26708984375	8.4737548828125	167.36041259765625	123
<ref>Bastian H, Bender R, Ernst AS, Kaiser T, Kirchner H, Kolominsky-	306.1416931152344	128.24517822265625	8.46820068359375	238.05117797851562	123
Rabas P, Lange S, Sawicki PT, Weber M (2006) Methoden. Köln:	323.0924987792969	138.2232666015625	8.46820068359375	221.11813354492188	123
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen	323.0924987792969	148.20135498046875	8.46820068359375	221.11471557617188	123
(IQWiG). Report No.: version 2.0</ref>	323.0924987792969	158.1226806640625	8.46820068359375	116.48773193359375	123
<ref>Bryan S, Brown J (1998) Extrapolation of cost-effectiveness information to	306.1416931152344	168.10076904296875	8.46820068359375	238.06527709960938	123
local settings. J Health Serv Res Policy 3(2):108–112</ref>	323.0924987792969	178.078857421875	8.4737548828125	172.44131469726562	123
<ref>Bytzer P (1999) Cost-effectiveness of gastroscopy. Ital J Gastroenterol	306.1408386230469	188.05694580078125	8.46820068359375	238.04367065429688	123
Hepatol 31(8):749–760</ref>	323.0916442871094	197.978271484375	8.4737548828125	79.42919921875	123
<ref>Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M,	306.1400146484375	207.95635986328125	8.46820068359375	238.08428955078125	123
Brazier J, O’Hagan T (2005) Probabilistic sensitivity analysis for	323.0908203125	217.9344482421875	8.4737548828125	221.1512451171875	123
NICE technology assessment: not an optional extra. Health Econ	323.0899658203125	227.85577392578125	8.46820068359375	221.152099609375	123
14(4):339–347</ref>	323.0899658203125	237.8338623046875	8.4737548828125	50.119903564453125	123
<ref>Cook JR, Drummond M, Glick H, Heyse JF (2003) Assessing the	306.1391906738281	247.81195068359375	8.46820068359375	238.06985473632812	123
appropriateness of combining economic data from multinational	323.0899963378906	257.7900390625	8.46820068359375	221.11740112304688	123
clinical trials. Stat Med 22(12):1955–1976</ref>	323.0899963378906	267.71136474609375	8.4737548828125	145.62933349609375	123
<ref>Demol P, Weihrauch TR (1997) Multi-national clinical therapy	306.13922119140625	277.689453125	8.468170166015625	238.07489013671875	123
studies. Design, management and costs (in German). Med Klin	323.09002685546875	287.66754150390625	8.468170166015625	221.1368408203125	123
(Munich) 92(2):117–123</ref>	323.09002685546875	297.6456298828125	8.4737548828125	84.30517578125	123
<ref>Drummond MF, Pang F (2001) Transferability of economic evaluation	306.1383972167969	307.56695556640625	8.46820068359375	238.08596801757812	123
results. In: Drummond MF, McGuire A (eds) Economic	323.0892028808594	317.5450439453125	8.46820068359375	221.12686157226562	123
evaluation in health care: merging theory with practice. Oxford	323.0892028808594	327.52313232421875	8.46820068359375	221.12924194335938	123
University Press, Oxford</ref>	323.0892028808594	337.501220703125	8.46820068359375	84.95382690429688	123
<ref>Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (1997)	306.1383972167969	347.422607421875	8.4737548828125	238.10635375976562	123
Methods for economic evaluation of health care programmes,	323.08917236328125	357.40069580078125	8.468170166015625	221.0836181640625	123
2nd edn. Oxford University Press, Oxford</ref>	323.08917236328125	367.3787841796875	8.468170166015625	144.59454345703125	123
<ref>Grieve R, Nixon R, Thompson SG, Normand C (2005) Using	306.13836669921875	377.30010986328125	8.46820068359375	238.035888671875	123
multilevel models for assessing the variability of multinational	323.08917236328125	387.2781982421875	8.46820068359375	221.1182861328125	123
resource use and cost data. Health Econ 14(2):185–196</ref>	323.08917236328125	397.25628662109375	8.473785400390625	190.54718017578125	123
<ref>Halliday RG, Darba J (2003) Cost data assessment in multinational	306.1375427246094	407.234375	8.46820068359375	238.06985473632812	123
economic evaluations: some theory and review of published	323.0883483886719	417.15576171875	8.468170166015625	221.15206909179688	123
studies. Appl Health Econ Health Policy 2(3):149–155</ref>	323.0883483886719	427.13385009765625	8.4737548828125	188.2794189453125	123
<ref>Hay J, Jackson J (1999) Panel 2: methodological issues in conducting	306.13671875	437.1119384765625	8.468170166015625	238.07244873046875	123
pharmacoeconomic evaluations–modeling studies. Value Health	323.0875244140625	447.09002685546875	8.4737548828125	221.1097412109375	123
2(2):78–81</ref>	323.0875244140625	457.0113525390625	8.473785400390625	37.381195068359375	123
<ref>Heyland DK, Kernerman P, Gafni A, Cook DJ (1996) Economic	306.1358947753906	466.98944091796875	8.46820068359375	238.06228637695312	123
evaluations in the critical care literature: do they help us improve	323.0867004394531	476.967529296875	8.46820068359375	221.14706420898438	123
the efficiency of our unit? Crit Care Med 24(9):1591–1598</ref>	323.0867004394531	486.888916015625	8.4737548828125	203.56869506835938	123
<ref>Hjelmgren J, Berggren F, Andersson F (2001) Health economic	306.13507080078125	496.86700439453125	8.468170166015625	238.06646728515625	123
guidelines—similarities, differences and some implications.	323.08587646484375	506.8450622558594	8.473785400390625	221.1361083984375	123
Value Health 4(3):225–250</ref>	323.0859069824219	516.8232421875	8.47369384765625	92.92242431640625	123
<ref>Jönsson B, Weinstein MC (1997) Economic evaluation alongside	306.13427734375	526.7445068359375	8.468215942382812	238.080078125	123
multinational clinical trials. Study considerations for GUSTO IIb.	323.0850830078125	536.7225952148438	8.46820068359375	221.17242431640625	123
Int J Technol Assess Health Care 13(1):49–58</ref>	323.0850830078125	546.70068359375	8.4737548828125	158.87445068359375	123
<ref>Kaplan GA, Keil JE (1993) Socioeconomic factors and cardiovascular	306.13427734375	556.6787719726562	8.46820068359375	238.0250244140625	123
disease: a review of the literature. Circulation 88(4 Pt 1):1973–	323.0850830078125	566.60009765625	8.4737548828125	221.1402587890625	123
1998</ref>	323.0850830078125	576.5781860351562	8.46820068359375	16.9364013671875	123
<ref>Koopmanschap MA, Touw KC, Rutten FF (2001) Analysis of costs	306.13427734375	586.5562133789062	8.46820068359375	238.071533203125	123
and cost-effectiveness in multinational trials. Health Policy 58	323.0850830078125	596.5343017578125	8.46820068359375	221.17999267578125	123
(2):175–186</ref>	323.0850830078125	606.4556274414062	8.47381591796875	41.61529541015625	123
<ref>Manca A, Willan AR (2006) ‘Lost in translation’: accounting for	306.1334533691406	616.4337158203125	8.4737548828125	238.10208129882812	123
between-country differences in the analysis of multinational cost-	323.0833740234375	626.4118041992188	8.46820068359375	221.15289306640625	123
effectiveness data. Pharmacoeconomics 24(11):1101–1119</ref>	323.0833740234375	636.3331298828125	8.4737548828125	199.12548828125	123
<ref>Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni	306.132568359375	646.3112182617188	8.46820068359375	238.1395263671875	123
C, Merot JL, Rossi F, vd Schulenburg JG, Souêtre E (1996) A	323.0833740234375	656.289306640625	8.468208312988281	221.17327880859375	123
multinational economic evaluation of rhDNase in the treat-	323.0833740234375	666.2673950195312	8.46820068359375	221.1409912109375	123
ment of cystic fibrosis. Int J Technol Assess Health Care 12	323.0833740234375	676.188720703125	8.46820068359375	221.0877685546875	123
(1):52–61</ref>	323.0833740234375	686.1668090820312	8.4737548828125	33.94140625	123
<ref>Moayyedi P (2007) The health economics of Helicobacter pylori	306.1325988769531	696.1448364257812	8.46820068359375	238.09945678710938	123
infection. Best Pract Res Clin Gastroenterol 21(2):347–361</ref>	323.0834045410156	706.1229248046875	8.47381591796875	203.36038208007812	123
J Public Health (2010) 18:327–335	51.02360153198242	33.0572509765625	8.4737548828125	121.04190444946289	124
<ref>O’Brien BJ (1997) A tale of two (or more) cities: geographic	51.02360153198242	57.03839111328125	8.4737548828125	238.0884895324707	125
transferability of pharmacoeconomic data. Am J Manag Care 3	67.97439575195312	66.959716796875	8.46820068359375	221.1419677734375	125
(Suppl):S33–S39</ref>	67.97439575195312	76.93780517578125	8.4737548828125	57.93010711669922	125
<ref>Ontario Ministry of Health and Long-Term Care (1994) Ontario	51.02360153198242	86.9158935546875	8.46820068359375	238.09022903442383	125
guidelines for economic analysis of pharmaceutical products.	67.97439575195312	96.89398193359375	8.46820068359375	221.11907958984375	125
Queen’s Printer for Ontario</ref>	67.97439575195312	106.8153076171875	8.4737548828125	93.80731201171875	125
<ref>Pang F (2002) Design, analysis and presentation of multinational economic	51.02360916137695	116.79339599609375	8.46820068359375	238.17313766479492	125
studies: the need for guidance. Pharmacoeconomics 20(2):75–90</ref>	67.97440338134766	126.771484375	8.4737548828125	208.89440155029297	125
<ref>Pinto EM, Willan AR, O’Brien BJ (2005) Cost-effectiveness analysis	51.02276611328125	136.74957275390625	8.4737548828125	238.08682250976562	125
for multinational clinical trials. Stat Med 24(13):1965–1982</ref>	67.97441101074219	146.6708984375	8.4737548828125	205.55284118652344	125
<ref>Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ,	51.02276611328125	156.64898681640625	8.46820068359375	238.116455078125	125
Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA et al	67.97355651855469	166.6270751953125	8.46820068359375	221.13514709472656	125
(2005) Conducting economic evaluations alongside multinational	67.97355651855469	176.54840087890625	8.46820068359375	221.11827087402344	125
clinical trials: toward a research consensus. Am Heart J 149	67.97355651855469	186.5264892578125	8.46820068359375	221.16395568847656	125
(3):434–443</ref>	67.97355651855469	196.50457763671875	8.4737548828125	41.615272521972656	125
<ref>Schöffski O, Graf von der Schulenburg JM (2007) Die Standardisierung	51.02191162109375	206.482666015625	8.46820068359375	238.13937377929688	125
der Methodik: Guidelines. In: Gesundheitsökonomische Evaluatio-	67.97355651855469	216.40399169921875	8.46820068359375	221.13429260253906	125
nen, 3 ed. Spinger, Berlin, pp 471–489</ref>	67.97355651855469	226.382080078125	8.4737548828125	125.83912658691406	125
335	531.5515747070312	33.0572509765625	8.46820068359375	12.7022705078125	126
<ref>Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl	306.1391296386719	57.04095458984375	8.46820068359375	238.07156372070312	127
H, Davis LM, Eastwood A (2004) Generalisability in economic	323.0899353027344	66.9622802734375	8.46820068359375	221.11569213867188	127
evaluation studies in healthcare: a review and case studies.	323.0899353027344	76.94036865234375	8.46820068359375	221.13943481445312	127
Health Technol Assess 8(49):iii–iv</ref>	323.0899353027344	86.91845703125	8.4737548828125	118.65896606445312	127
<ref>Siebert U (2003) When should decision-analytic modeling be used in	306.13916015625	96.89654541015625	8.46820068359375	238.11053466796875	127
the economic evaluation of health care? Eur J Health Econ	323.0899658203125	106.81787109375	8.46820068359375	221.152099609375	127
4:143–150</ref>	323.0899658203125	116.79595947265625	8.4737548828125	36.172760009765625	127
<ref>Thompson SG, Nixon RM, Grieve R (2006) Addressing the issues	306.1383056640625	126.7740478515625	8.46820068359375	238.10040283203125	127
that arise in analysing multicentre cost data, with application to a	323.089111328125	136.75213623046875	8.46820068359375	221.17498779296875	127
multinational study. J Health Econ 25(6):1015–1028</ref>	323.089111328125	146.6734619140625	8.4737548828125	179.9281005859375	127
<ref>Willan AR, Pinto EM, O’Brien BJ, Kaul P, Goeree R, Lynd L,	306.1383361816406	156.65155029296875	8.4737548828125	238.08853149414062	127
Armstrong PW (2005) Country specific cost comparisons from	323.0899963378906	166.629638671875	8.46820068359375	221.15377807617188	127
multinational clinical trials using empirical Bayesian shrinkage	323.0899963378906	176.55096435546875	8.46820068359375	221.11489868164062	127
estimation: the Canadian ASSENT-3 economic analysis. Health	323.0899963378906	186.529052734375	8.46820068359375	221.11141967773438	127
Econ 14(4):327–338</ref>	323.0899963378906	196.50714111328125	8.4737548828125	70.18869018554688	127
<ref>Willke RJ, Glick HA, Polsky D, Schulman K (1998) Estimating	306.13836669921875	206.4852294921875	8.46820068359375	238.03759765625	127
country-specific cost-effectiveness from multinational clinical	323.08917236328125	216.40655517578125	8.46820068359375	221.09368896484375	127
trials. Health Econ 7(6):481–493</ref>	323.08917236328125	226.3846435546875	8.4737548828125	112.53814697265625	127